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Background: Facial lipoatrophy is a frequently reported condition associated with use of antiretroviral (ARV) drugs.
Poly-L-lactic acid (PLLA) acid has been used to correct facial lipoatrophy in people with HIV since 2004 both in
Europe and the United States. The objective of this study was to establish, in real life conditions and in a large
sample, the safety of PLLA (New Fill®, Valeant US, Sinclair Pharma Paris, France) to correct facial lipoatrophy
among HIV-positive patients.
Methods: A longitudinal study was conducted between 2005 and 2008 in France. Data from 4,112 treatment
courses (n = 4,112 patients) and 15,665 injections sessions (1 to 5 injection sessions per treatment course) were
gathered by 200 physicians trained in the use of PLLA.
Results: The average age of patients (88.3% males) treated for lipoatrophy was 47.1 ± 8.1 years (Mean ± SD);
91.2% of patients had been receiving ARV treatment for 10.9 (±4.2) years; CD4 T-cell count was 535 ± 266 cells/
mm3. The duration of facial lipoatrophy was 5 ± 2.8 years and the severity was such that 47.3% of patients required
five injection sessions of PLLA and 81.9% of the sessions required two vials of the preparation. The final visit, scheduled
two months after the last injection session, was attended by 66.0% of patients (n = 2,713). 48 treatment courses (2.8%)
were discontinued due to adverse events (AEs). The overall incidence of AEs per course was 18.8%. Immediate AEs,
bleeding (3.4%), bruising (2.3%), pain (2.0%), redness at injection site (1.6%), and swelling of the face (0.7%), occurred in
15.4% of courses and 7.0% of sessions (usually during the first session). Non-immediate AEs, mainly nodules (5.7%),
inflammation (0.7%), granuloma (0.3%), discolouration (0.2%), and skin hypertrophy (0.1%), occurred in 6.7% of courses.
Non-immediate AEs occurred within a time ranging from 21 days (inflammation) to 101 days (granuloma) and all
but three of the 13 cases of granuloma resolved. Product efficacy was rated satisfactory by 95% of the patients and
physicians.
Conclusions: This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible,
efficient, and safe when performed by trained physicians.
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Lipodystrophy syndrome is a cluster of long term side
effects associated with antiretroviral (ARV) therapy used
for human immunodeficiency virus (HIV) infection [1].
The syndrome is associated with lipohypertrophy, char-
acterised by enlargement of the dorsocervical fat pad,
thickening of the neck, breast enlargement, abdominal
visceral fat accumulation, and lipomata, and/or lipoatro-
phy, manifested as fat loss from the face, arms, legs, but-
tocks, and the trunk. Morphological changes are commonly
accompanied by metabolic disorders (hyperlipidaemia, insu-
lin resistance and hyperglycaemia). Approximately half of all
patients treated for HIV in France are affected with lipoatro-
phy [2] and choice of treatment for these individuals is
largely complicated by this condition [3].
The prevalence of facial lipoatrophy is high. In a recent
cross-sectional study in France 54% of patients treated for
a median of 10 years presented facial lipoatrophy, and
28% of patients had been receiving treatment for less than
5 years [2]. Facial lipoatrophy has a negative impact on
Health Related Quality of Life (HRQoL) [4,5] and stigma
related to altered facial features can lead to suboptimal ad-
herence to ARV treatment [6]. For these reasons, cor-
rection of facial lipoatrophy is an integral part of the
management of HIV positive patients who present with
this problem [7].
To date there is no curative medical treatment for facial
lipoatrophy; therapeutic options are limited to cosmetic
surgery using autologous adipose tissue, or injections of
fillers that may be permanent or absorbable to plump
sunken cheeks [8]. New Fill®, poly-L-lactic acid (PLLA,
Valeant US, Sinclair Pharma, Paris, France), is a bio-
compatible, resorbable, sterile, non-pyrogenic product
introduced to the European market and used in cos-
metic surgical procedures in France since 1999, and to
correct facial lipoatrophy in people with HIV in Europe
and the United States since 2004 where it is adminis-
tered via a deep intradermal injection. Currently New
Fill® is the only product reimbursed in France in this
indication [9].
Despite this apparently widespread usage, to the best
of our knowledge, no study has evaluated the safety of
this treatment in real-life conditions in a large number
of people with HIV affected by facial lipoatrophy. There-
fore, the aim of this study was to establish the safety,
efficacy, and conditions for use of PLLA in that popu-
lation. The ancillary study of this cohort evaluating
Health Related Quality of Life (HRQoL) in 230 of the
4,112 patients included in the current study, was pub-
lished elsewhere [10]: and the data showed that 64.4%
of the patients reported HRQoL improvement greater
than 10% 2 months after the procedure, and 58.8% at
12–18 months with 95% of both patients and investi-
gators reporting satisfaction with the PLLA treatment.Methods
Study design and patients
This was an observational, longitudinal, multicentre, open
label study conducted in France from 25 February 2005 to
28 February 2008. While the primary objective was to de-
scribe the safety of Poly-L-lactic acid for treatment of fa-
cial lipoatrophy in the context of HIV, the efficacy of the
treatment, the description of its use in real life and the
adequacy of prescription compared with the recom-
mendations of the French Commission for the Evaluation
of Products and Services (EPSA) [11] were secondary
objectives.
The study was conducted in accordance with EPSA re-
quirements. All French physicians trained in the use of
PLLA were invited to participate; those agreeing were
provided with systematic monitoring notebooks to docu-
ment information related to the procedure on all pa-
tients treated with PLLA. The prerequisite that any
physician wishing to prescribe PLLA in France should
undergo training facilitated the ascertainment of patients
in this study since the researchers were then able to con-
tact all physicians enrolled as PLLA prescribers, seek
their participation in the study and utilize the data gath-
ered systematically in usual care through monitoring
notebooks.
Verbal informed consent was obtained for all patients
by investigators. The study was approved by the Paris Ile
de France 4 Ethics Committee, Paris, France. It was con-
ducted in compliance with the Helsinki Declaration [12],
with the French Data Processing and Liberties Law no
78.17 of 06.01.1978, received a favourable opinion from
the CCTIRS (French Consultative Committee on Data
Processing in Research in the field of Health), and was
authorised by CNIL (French National Commission on
Data Processing and Liberties).
Data collection
Follow-up visits were planned at the beginning of each
course before the first injection of PLLA, then at each
injection session, and finally, two months after the end
of treatment, representing a treatment course corre-
sponding to the entire process by PLLA for a given
patient.
At baseline, the patient demographics, date of HIV diag-
nosis, the duration of facial lipoatrophy, current ARV
therapy, CD4+ T-lymphocyte count, HIV viral load, and
the history of previous treatments by the PLLA before this
study were collected by physicians in the systematic moni-
toring notebook.
At each injection session, the physician recorded the
conditions of PLLA reconstitution and the number of
vials used. Adverse side-effects, which may have been re-
lated to the injections and including those that occurred
subsequently to the previous session, were also documented.
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the patient gave a subjective assessment of the effectiveness
of the treatment on a four-point scale (very satisfied to very
dissatisfied) and made a decision whether they would
repeat the treatment or not within 12 to 18 months. If
the treatment was stopped before the recommended
five sessions of injections the reasons, including intol-
erability, were collected.
The collection of data was consistent for all patients
and patients undergoing more than one course of treat-
ment could be included in the study.
Treatment
A complete treatment course included one to five ses-
sions of injections, each one month apart. At each treat-
ment session the physician injected one or two vials of
PLLA, depending on the severity of lipoatrophy, into the
dermis. Consistent with the product instructions current
at the initiation of the study, the product was to be
reconstituted at least 2 hours prior to administration
with a recovery window of 2 to 72 hours, using 3 to
5 ml of sterile water for injection by 150 mg PLLA vial.
Data analysis and statistics
Analyses focused on the data set of patients who re-
ceived at least one injection session. The mean, standard
deviation (SD), median, and first and third quartiles
(Q1-Q3) were used to present continuous variables; cat-
egorical data were summarized by the number (N) and
the percentage of each response category.
Adverse events (AEs) were classified into 2 categories:
(1) immediate AEs, contemporary to injections or (2)
non-immediate AEs, of later onset, resulting from the ef-
fect of several successive injections sessions. Immediate
AEs reported in the summary of product characteristics
and listed in the monitoring notebook were: bleeding,
pain, redness at injection site, bruising, and swelling of
the face; non-immediate AEs reported in the summary
of product characteristics and listed the notebook were:
nodules (i.e., nodules, papules, induration), inflamma-
tion, discolouration, granuloma, allergic reaction, skin
hypertrophy, and skin atrophy. Non-listed AEs that were
reported during the study were classified as “Other AE.”
The impact of immediate AEs is presented by injection
session and by treatment course (as treatment courses
could vary in the number of injections) and the impact of
non-immediate AEs by course, since non-immediate AEs
could not be attributed with certainty to a particular
session.
The impact of the length of the training of physicians
and the injections rank number (1st, 2nd…) on immedi-
ate AEs was explored using a mixed model [13] with the
“doctor” and “course of treatment” as random effects
and “the injection rank number” and “length of training”(<1 year, 1–3 years, > 3 years) as fixed effects. Similarly,
the number of non-immediate AEs was explored using a
mixed model with the “doctor” as a random effect and
the “length of training” as a fixed effect. Similar models
have been used to study the impact of the volume of
water used for reconstitution (<3, 3–5, > 5 ml) on the
number of AEs. Statistical analyses were performed
using SAS software release 8.02 (SA Institute, Cary, NC)
and AdClin version 3.0 (AdClin, Paris, France).
Results
Of the 386 physicians trained in the use of PLLA, 272
actually treated patients with PLLA, and 200 returned at
least one fully completed systematic monitoring note-
book. Physicians were dermatologists (46.5%), plastic
surgeons (42.4%), infectious disease specialists (4.5%), or
general practitioners (6.6%). The majority (59.7%) had
been trained in the use of PLLA for less than a year
(mean ± SD: 1.7 ± 2.5 years, median: 0.5 years, Q1-Q3:
0.1 to 2.2 years). The characteristics of the 200 physi-
cians participating in the study were comparable to the
whole sample of trained physicians in France.
Data from 4,112 treatment courses (i.e., 4,112 HIV-
positive patients) and 15,665 injection sessions were ana-
lysed. The vast majority (88.3%) of patients were men.
Their median age was 45.8 years (mean ± SD: 47.1 ±
8.1 years). At baseline, the mean time since first diagno-
sis of facial lipoatrophy was 5 years (5 ± 2.8 years), that
of HIV seropositivity was 15.3 (15.0 ± 4.7 years), and
duration of ARV drug treatment, 10.9 years (10.9 ±
4.2 years). Notably, 8.8% of patients had no history of
ARV therapy when they initiated treatment with PLLA.
For patients treated with ARV drugs, current regimens
included 34% who were receiving a combination of
two nucleoside reverse transcriptase inhibitors (NRTIs)
and one protease inhibitor boosted with ritonavir; 21%
who were receiving two NRTIs and one non-nucleoside
reverse transcriptase inhibitors (NNRTI), and 6.7% were
taking three NRTIs. Patients included in the study had 85
different ARV regimens. In 70.6% of patients, the viral
load was below 400 copies/ml; mean CD4 t-cell count was
535 ± 266 cells/mm3. At the commencement of the study
39.7% of patients had a prior history of corrective treat-
ment with PLLA.
The product was used in line with recommended con-
ditions. There was a median time between reconstitution
and administration of 24 hours (2–72 hours 94.8% of
cases) and a median volume recovery of 5 ml (3–5 ml in
80.2%). Two bottles of product were used in 81.9% of in-
jections sessions. The median time between two succes-
sive sessions ranged from 35 days between sessions 1
and 2 to 42 days between sessions 4 and 5. The final
visit, scheduled two months after the last injection ses-
sion, took place in 66.0% of cases (2,713 patients) and at
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(Q1-Q3: 2–3.7 months). The subjective evaluation of the
effectiveness of the treatment on the four-point scale
during this visit was very satisfactory, physicians judging
the result “satisfied” or “very satisfied” in 95.4% of the
cases, and patients in 95.6% (Figure 1).
For 47.3% of patients, five sessions of injections were
attended (3.8 sessions on average per treatment course),
representing one treatment with a total of 15,665 injec-
tions sessions. For 79% of 2,168 patients who had less
than five sessions, reasons for discontinuation were indi-
cated (n = 1713) and more than one reason for stopping
was possible for a single patient. In 54.8% of cases, the
result was considered sufficiently satisfactory to stop the
course of injections. In the 27.8% of the cases with rea-
sons for discontinuation documented, the treatment was
stopped because the patients did not return for follow-
up. In only 48 patients (2.8%), was treatment discontin-
ued because of adverse events and these were noted to
be: 25 cases of nodule/induration, eight cases of pain,
and seven cases of granuloma. During the study one pa-
tient suffered from a myocardial infarction and another
died. However, the pharmacovigilance investigation sub-
sequently ruled out any association with the PLLA treat-
ment. One or more AEs were reported in 18.8% of the
treatment courses; immediate AEs (15.4%) occurred
more frequently than non-immediate AEs (6.7%).
From all treatment courses 66% of the records were
available at the visit 2 months (Q1-Q3: 2–3.7 months)
after the last injection session. The percentage of injection
sessions associated with at least one AE was greater in the
group with an evaluation available at 2 months after the
last injection session (7.7%, n = 11,358 injections) than in
the group lost to follow up (5.3%, n = 4,307).
A total of 1,577 immediate AEs that may have been re-
lated to the injections were reported during 1,104 of the
15,665 documented injection sessions (overall incidence:
7.0%). Immediate AEs were: bleeding (reported in 3.4%


























Figure 1 Subjective evaluation of treatment effectiveness by
patients and physicians (percentage).the injection site (1.6%), and localized oedema of the
face (0.7%). Most of these events resolved spontaneously:
a decrease was observed in 92.3% of cases for bruising,
92.6% for pain, 89.8% for redness at injection site, and
96% for swelling of the face (Table 1). An analysis of im-
mediate AEs, performed on 2,808 systematic monitoring
notebooks for which all required data were available,
showed that the number of AEs decreased significantly
with injections within one course: the overall incidence
of immediate AEs declined from 9.9% at the first injec-
tion session to 4.6% at the fifth injection session (p <
0.0001). There was no relationship between the number
of immediate AEs and length of training of physicians
(p = 0.08) nor with the volume of water used for recon-
stitution (p = 0.03; not significant given the level of sig-
nificance set at 1% to account for the multiplicity of
tests). Immediate AEs were reported for 5.7% of injec-
tions sessions (3/53) where the volume recovery was less
than 3 ml, 7.4% of the sessions where it was between 3
and 5 ml (894/12,165), and 5.6% if more than 5 ml (165/
2946).
Non-immediate AEs which may have been related to
injections (294 in total) were reported during 274 of the
4,112 documented treatment courses (6.7%) and were
reported as nodule/induration (in 5.7% of courses), in-
flammation (27 cases, 0.7%), granuloma (13 cases,
0.3%), discolouration (9 cases, 0.2%), skin hypertrophy
(6 cases, 0.1%), allergic reaction (3 cases, 0.1%), and skin
atrophy (2 cases, 0.0%). The median time to onset was
21 days for inflammation, 56 days for nodule/indur-
ation, almost 100 days for hypertrophy skin, discolour-
ation, and granuloma (Table 2). The regression of signs
could be observed in all documented cases with the
exception of three cases of granuloma. However, this
result must be qualified by the large number of
missing data (respectively 172/234, 8/27, 4/13, 7/9, 5/6,
and 2/3 for nodule/induration, inflammation, granulomas,
discoloration, skin hypertrophy, and allergic reaction)
(Table 2).
Neither the “duration of the training of physicians”





Bleeding 529 (3.4%) [3.1%; 3.7%] 425/455 (93.4%)
Bruising 365 (2.3%) [2.1%; 2.6%] 299/324 (92.3%)
Pain 319 (2.0%) [1.8%; 2.3%] 264/285 (92.6%)
Redness at point
of injection
257 (1.6%) [1.4%; 1.9%] 212/236 (89.8%)
Facial oedema 107 (0.7%) [0.6%; 0.8%] 97/101 (96.0%)
1n (%) [CI 95% exact].
2n (% calculated on documented data).
Table 2 Non- immediate AEs by treatment course (n = 4,112)
Incidence1 per course Delay of onset (days)2 Regression of AEs3
Nodule/induration 234 (5.7%) [5.0 %; 6.4 %] 55 [29 – 91] 62/62 (100%)
Inflammation 27 (0.7%) [0.4%; 1.0%] 21 [0 – 57] 19/19 (100%)
Granuloma 13 (0.3%) [0.2%; 0.5%] 101 [69 – 117] 6/13 (46%)
Decolouration 9 (0.2%) [0.1 %; 0.4%] 92 [11 – 138] 2/2 (100%)
Skin hypertrophy 6 (0.1%) [0.1%; 0.3%] 84 [40 – 93] 1/1 (100%)
Allergic reactions 3 (0.1%) [0.0%; 0.2%] 1 [0 – 94] 1/1 (100%)
Skin atrophy 2 (0.0%) [0.0%; 0.2%] 66 [13 – 119]4 -
1n (%) [CI 95% exact].
2Median [Q1 – Q3] (calculated on documented data).
3n (% calculated on documented data).
4Reported values for the 2 cases.
A treatment course had a mean of 3.8 injections.
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of non-immediate AEs.
Besides the expected and listed AEs, 72 AEs considered
as possibly related to PLLA injections were classified as
“other” (overall incidence: 0.5%). Discomfort (19 cases,
0.1%), tingling (11 cases, 0.1%), hematoma (5 cases, 0.0%),
and folliculitis cheeks (4 cases, 0.0%) were the only events
reported more than 3 times during the 15,665 injection
sessions. Only one case of cutaneous necrosis met the cri-
terion of gravity (according to French Adverse Event
reporting procedures) and was reported a serious AE, but
the necrosis resolved.
Discussion
This 3-year observational study (2005–2008) describes
the safety, efficacy, and use of PLLA in France via a
comprehensive collection of information on a large sam-
ple of HIV-positive patients presenting with facial lipoa-
trophy and treated with PLLA. The patients in this
observational study were older and more likely to be
men than the patients with long-term HIV disease over
the period 2006–2008 followed in the French Hospital
Database on HIV [3] and the wide variety of ARV regi-
mens reflects the long exposure to ARV treatment. Viro-
logical control (<400 copies/ml) was achieved in 70.6%
of patients, suggesting that therapeutic success was
lower in this population than in comparison with all
French ARV treated patients (88% < 500 copies/ml in
2007). This may be explained by the fact that patients in
this sample had been exposed for a longer period to anti-
retroviral drug toxicity. Treatment failure had led to more
frequent switches than was seen in the French Hospital
Database. Moreover, the lower limit of detectability of
viral load in our study was different than that reported for
the French population during the same period.
The vast majority of AEs reported were mild and tran-
sient and only one serious AE (skin necrosis) was re-
ported. The overall incidence rate of AEs was only
around one fifth of treatment courses, and immediateAEs occurred more frequently than non-immediate AEs
which were less than seven percent. The immediate im-
pact of AEs decreased with the number of injections ses-
sions and did not depend significantly, on the duration
of physicians’ training to use the product, or the volume
of reconstitution. Essentially, immediate AEs (bleeding,
bruising, pain, redness and oedema) were related to the
injection technique and non-immediate AEs could be re-
lated to the product itself but arguably also to the product
reconstitution or injection technique. Nodule/induration
was rare and other non-immediate AEs (granuloma, in-
flammation, discolouration, allergic reaction, skin atrophy,
or skin hypertrophy) occurred in less than 1% of patients.
Reasons for discontinuation were reported for 1713 pa-
tients and only 48 courses (2.8%) were discontinued due
to the occurrence of AEs, mostly non immediate but
injection-related AEs may occur with any injectable filler
and generally resolve spontaneously.
Prior to this study, 12 studies on the safety of PLLA
[14-25] involving a total of 744 HIV-positive patients
treated with PLLA with study numbers ranging from 20
patients [17] to 115 patients [24], have been published
and no serious AEs associated with the use of PLLA
were reported. However, immediate AEs were more fre-
quently reported in these studies than the one reported
here. Carey and colleagues (2007) noted that [15] 76% of
the patients complained of pain or discomfort, 64% of
localised oedema, and 53% of erythema. In the study by
Lafaurie et al. [18] 77% of the patients reported pain and
4% bruising or bleeding at the injection site. Moyle et al.
[21] reported that 38% of patients in their study had
contusions, 10% inflammation, discomfort and erythema,
and 7% oedema. While Cattelan et al. [16] observed that
30% of patients had oedema and 24% bruising at the in-
jection site. Finally Mest and Humble [20] noted that
30% of patients had a haematoma. Several reasons might
explain these variations such as differential reporting be-
tween physicians (e.g. a transient local swelling after
subcutaneous injection of 4 ml is unavoidable), different
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study, immediate AEs were noted after each session. It is
likely that weekly evaluations would have been more
precise for assessing non-immediate AE. However, since
this was an observational cohort study without modifica-
tion of usual clinical care, a one month recall period was
chosen.
Nodule is the most commonly observed non-immediate
AE observed in the cosmetic procedure, but with varying
frequency depending on the study. Orlando et al. [24] re-
ported that 45% of the 91 patients followed for 48 weeks
had invisible but palpable, subcutaneous micronodules,
nearly eight times higher than in our study. Palpable,
intraoral, intradermal papules were reported in 8 of 20 pa-
tients by Guaraldi et al. [17] and in 9 of 30 patients by
Moyle et al. [21]. Three other studies have reported nod-
ules with a frequency of about 10% [15,18,22]. These au-
thors also reported cases of papules at the injection site in
12% of patients, as did Mest and Humble [20]. Other
studies have reported this type of AE with a lower fre-
quency, if at all [16,19,25]. In our large-scale real life study,
physicians reported the frequency of nodules at 5.7%.
The usage of PLLA across Europe and the United
States for the correction of cutaneous depressions be-
came widespread. The safety profile of PLLA has im-
proved dramatically over recent years with increased
experience in product preparation, in selection of injec-
tion area and in injection modalities. In particular a de-
creased risk of adverse reactions with an increased
dilution was noted in several clinical trials and in the In-
jectable Filler Safety Study [26].
Our study has a number of limitations. Of the 272
physicians who treated patients with PLLA and agreed
to participate to the study, 72 did not return notebooks
but we also had no knowledge of whether a physician
started a notebook but did not submit it. In addition,
34% of patients were not evaluated 2 months after the
last injection. However, it is most likely that the oc-
currence of adverse effects would have encouraged the
patient to return to the trained doctor rather than to
another who was not familiar with the use of the
product and did not perform the procedure.
Nevertheless, the strength of this study is the large
sample size, over 4,000 people treated with PLLA versus
less than 100 for most other published studies and with
only a small number of discontinuations for intolerable
adverse effects. Furthermore, the safety of this treatment
for the correction of lipoatrophy in people with HIV has
been demonstrated in real life conditions.
Conclusions
This prospective, observational study examined the safety
of poly-L-lactic acid for the correction of facial lipoatro-
phy in HIV patients. This was a large study involvingmore than 4,000 treatment courses, and 15,000 injection
sessions of PLLA were used to treat patients with severe
facial lipoatrophy. One quarter of the patients required
five treatment sessions and 82% of sessions required the
use of two vials of PLLA. The subjective efficacy of the
treatment was reported as “satisfied” or “very satisfied” by
most patients and physicians. The product was well
tolerated and the incidence of immediate and non-
immediate AEs was acceptable. The vast majority of
AEs reported were mild and transient and immediate
AEs occurred more often during the first injection ses-
sion than in subsequent sessions. Nodule/induration
was rare and granuloma occurred seldomly. Less than
3% of the PLLA treatments were discontinued due to
an adverse event, despite the large number of injec-
tions carried out, and no new adverse events of PLLA
were described. We have demonstrated in real-life con-
ditions that, in the hands of trained physicians, treat-
ment of ARV toxicity-induced facial lipoatrophy with
poly-L-lactic acid (New Fill®) is feasible, efficient, and
safe in clinical practice.
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